The Neurology Minute® podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, PhD, FAAN, with contributions by experts from the Neurology® journals, Neurology Today®, Continuum®, and more.
Fregoli syndrome is the recurrent belief that different people are one familiar person in disguise. Later-life onset should raise concern for neurodegenerative disease, while dopaminergic medication is another potential contributor requiring review.
Virus-specific T cells can provide biological control of JC virus as a bridge to stem cell transplantation in progressive multifocal leukoencephalopathy with inherited immune deficiency, but they do not correct the underlying genetic defect and recurrence risk remains uncertain.
Primary motor cortex involvement in brain metastases is associated with greater seizure risk both at diagnosis and afterwards, but retrospective evidence supports counselling and seizure awareness rather than proving that prophylactic anti-seizure medication improves outcomes.
Capgras syndrome combines preserved face recognition with loss of normal emotional familiarity and a belief that an identical impostor has replaced someone known, requiring distinction from prosopagnosia, name-recall difficulty and other forms of misidentification.
Delusional misidentification involves fixed beliefs about abnormal familiarity and occurs in psychiatric and neurological disease; new onset in an older adult without a clear trigger should raise concern for neurodegeneration and prompt direct enquiry and caregiver support.
TNF alpha helps maintain protective tuberculosis granulomas but also contributes to damaging inflammation in tuberculous meningitis; steroids remain the initial anti-inflammatory adjunct, while infliximab may be considered for persistent or relapsing inflammation after steroid failure.
An AAN advocacy update describes BrainPAC’s candidate scorecard and opposition to proposed hospital outpatient botulinum toxin prior authorisation and a separate 50% same-day service payment reduction, while distinguishing both proposals from implemented policy.
Newer myasthenia gravis treatments show comparable reductions in QMG and MgAdL scores in the reported network meta-analysis, leaving administration, cost, treatment response and patient preferences important when clinicians and patients choose between available options.
The HARVEST trial finds no survival benefit from rifampicin 35 mg/kg compared with 10 mg/kg in tuberculous meningitis, with possible harm; increased dexamethasone metabolism offers one proposed mechanism and supports retaining standard rifampicin dosing.
Safer clinical artificial intelligence use depends on recognising incorrect outputs, potential reuse of sensitive information and environmental costs; training should address these risks while acknowledging that electronic records, workflows and patient encounters differ across healthcare systems.
.svg)